| Code | CSB-RA721905MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to TGI-2, targeting PVRIG (PVR-related immunoglobulin domain-containing protein), also known as CD112R. PVRIG functions as an inhibitory immune checkpoint receptor expressed on T cells and NK cells that binds to its ligand PVRL2 (CD112), delivering negative signals that suppress immune cell activation and cytotoxic function. This checkpoint pathway represents an important mechanism by which tumors evade immune surveillance, as PVRL2 is frequently upregulated on various cancer cells. PVRIG co-expression with other checkpoint receptors like PD-1 and TIGIT has been observed in tumor-infiltrating lymphocytes, contributing to T cell exhaustion in the tumor microenvironment.
TGI-2 is a reference antibody used in preclinical research investigating PVRIG blockade as a cancer immunotherapy strategy. This biosimilar antibody serves as a valuable research tool for studying PVRIG-mediated immune regulation, evaluating combination checkpoint blockade approaches, and exploring mechanisms of tumor immune evasion. It enables investigators to assess the therapeutic potential of targeting the PVRIG/PVRL2 axis in oncology and immunology research.
There are currently no reviews for this product.